906
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach

ORCID Icon, &
Pages 13747-13758 | Received 12 Mar 2021, Accepted 11 Oct 2021, Published online: 28 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Basavarajaiah Suliphuldevara Mathada, N. Jeelan Basha, Mohammad Javeed, Prashantha Karunakar, Adavala Venkatesulu, Krishnakanth Erappa & A. Varsha. (2023) Novel pyrimidines as COX-2 selective inhibitors: synthesis, DFT analysis, molecular docking and dynamic simulation studies. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-14.
Read now

Articles from other publishers (4)

Xue-Ning Wang, Byu-Ri Sim, Hong Chen, Yun-Xiao Zheng, Jun-Biao Xue, Lei Wang, Wei-Sha Kong, Kuan Zhou, Shu-Juan Guo, Jing-Li Hou, Jiong Zhang, He-Wei Jiang & Sheng-Ce Tao. (2022) Identification of sitagliptin binding proteins by affinity purification mass spectrometry. Acta Biochimica et Biophysica Sinica 54:10, pages 1453-1463.
Crossref
Ghazala Muteeb, Md Tabish Rehman, Mohamed F. AlAjmi, Mohammad Aatif, Mohd Farhan & Sheeba Shafi. (2022) Identification of a Potential Inhibitor (MCULE-8777613195-0-12) of New Delhi Metallo-β-Lactamase-1 (NDM-1) Using In Silico and In Vitro Approaches. Molecules 27:18, pages 5930.
Crossref
Kaifu Gao, Rui Wang, Jiahui Chen, Limei Cheng, Jaclyn Frishcosy, Yuta Huzumi, Yuchi Qiu, Tom Schluckbier, Xiaoqi Wei & Guo-Wei Wei. (2022) Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Chemical Reviews 122:13, pages 11287-11368.
Crossref
Ghazala Muteeb, Abdulrahman Alsultan, Mohd Farhan & Mohammad Aatif. (2022) Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach. Molecules 27:4, pages 1283.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.